India

Covaxin Cleared for 6-12 Age Group, Corbevax for 5-12-Year-Olds

The DCGI also granted emergency use authorisation to Corbevax for children between the age of 5-12 years

New Delhi:

The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech’s Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.

The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO).

The DCGI has directed the vaccine maker to submit the safety data, including the data on the adverse events, with due analysis every 15 days for the first two months. Thereafter, Bharat Biotech has been asked to submit the data monthly for up to 5 months.

Covaxin was granted Emergency Use Listing (EUL) by the DCGI for the age group of 12 to 18 years on December 24, 2021. It’s currently being administered to those in the 15-18 age group.

The DCGI has also granted emergency use authorisation to Corbevax for children between the age of 5-12 years. The vaccine is currently being administered to those in the age group of 12-14.

 

The Gulf Indians

Recent Posts

Denial of Bail to Umar Khalid and Sharjeel Imam Unjust : The Supreme Court once again upholds the principle ‘ Bail is the Rule , Jail the Exception ‘

By Joseph Maliakan In a judgment that will have far-reaching consequences for the protection of…

1 week ago

The proposed School Management Committees (SMCs) are Unconstitutional, an attack on Autonomy and will spread utter Chaos in School Education across the country.

By Joseph Maliakan Education according to the Indian Constitution, is in the concurrent list and…

3 weeks ago

Brutal Opression of Labour in NOIDA : May Day becomes Black Day

By Joseph Maliakan " Workers of the World United ! You have nothing to loose…

4 weeks ago

Death of the Dalit Nithin Raj – Institutional Muder

By Joseph Maliakan Nithin Raj 22, a dalit , son of Latha , a daily…

1 month ago

This website uses cookies.